Compare Nerdwallet Inc (NRDS) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

NRDS trades at $9.55, down 2.75% today, but maintains strong fundamentals with a P/E of 10.71 and P/S of 0.8, indicating potential undervaluation. The company has shown consistent revenue growth from $539M in 2022 to $837M in 2025, with net income turning positive since 2024. Recent Q2 2026 earnings missed expectations at $0.07 per share versus $0.0934 expected, though Q1 and Q4 2025 beat estimates. Technical indicators show a bullish trend with strong moving average signals, though RSI levels suggest potential overbought conditions.

The outlook for NRDS remains positive with analyst consensus at 66.7% buy ratings and projected 27.9% upside potential. Strong profitability metrics include 93.5% gross margins and 18.16% ROE. Key risks include competitive pressures in financial guidance markets and reliance on organic search traffic. The company's improving cash flow from operations ($132M in 2025) supports continued growth initiatives in personal loans and deposit accounts.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.